Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Adrenomyeloneuropathy
NCT03864523Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in adrenomyeloneuropathy (AMN). Primary endpoint: 2 Minute Walk Test at 24 months. Started Jan 2016; status: completed.
02
Drugs
pioglitazone
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on NCT03864523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864523.